Medicxi's mega-startup Centessa rolls out first data for hemophilia drug with plans to charge ahead into pivotal test

Kyle Blankenship

When Medicxi earlier this year cobbled together Centessa — its Russian nesting doll of a biotech startup with 10 portfolio companies folded into one — the focus …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Medicxi's mega-startup Centessa rolls out first data for hemophilia drug with plans to charge ahead into pivotal test

Kyle Blankenship

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

It's been three months without a biotech IPO

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Medicxi's mega-startup Centessa rolls out first data for hemophilia drug with plans to charge ahead into pivotal test